Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia

Shah, Kinjal LU ; Nasimian, Ahmad LU ; Ahmed, Mehreen LU ; Al Ashiri, Lina LU orcid ; Denison, Linn LU ; Sime, Wondossen LU ; Bendak, Katerina ; Kolosenko, Iryna ; Siino, Valentina LU and Levander, Fredrik LU orcid , et al. (2023) In Blood Cancer Journal 13(1).
Abstract

The deregulation of BCL2 family proteins plays a crucial role in leukemia development. Therefore, pharmacological inhibition of this family of proteins is becoming a prevalent treatment method. However, due to the emergence of primary and acquired resistance, efficacy is compromised in clinical or preclinical settings. We developed a drug sensitivity prediction model utilizing a deep tabular learning algorithm for the assessment of venetoclax sensitivity in T-cell acute lymphoblastic leukemia (T-ALL) patient samples. Through analysis of predicted venetoclax-sensitive and resistant samples, PLK1 was identified as a cooperating partner for the BCL2-mediated antiapoptotic program. This finding was substantiated by additional data obtained... (More)

The deregulation of BCL2 family proteins plays a crucial role in leukemia development. Therefore, pharmacological inhibition of this family of proteins is becoming a prevalent treatment method. However, due to the emergence of primary and acquired resistance, efficacy is compromised in clinical or preclinical settings. We developed a drug sensitivity prediction model utilizing a deep tabular learning algorithm for the assessment of venetoclax sensitivity in T-cell acute lymphoblastic leukemia (T-ALL) patient samples. Through analysis of predicted venetoclax-sensitive and resistant samples, PLK1 was identified as a cooperating partner for the BCL2-mediated antiapoptotic program. This finding was substantiated by additional data obtained through phosphoproteomics and high-throughput kinase screening. Concurrent treatment using venetoclax with PLK1-specific inhibitors and PLK1 knockdown demonstrated a greater therapeutic effect on T-ALL cell lines, patient-derived xenografts, and engrafted mice compared with using each treatment separately. Mechanistically, the attenuation of PLK1 enhanced BCL2 inhibitor sensitivity through upregulation of BCL2L13 and PMAIP1 expression. Collectively, these findings underscore the dependency of T-ALL on PLK1 and postulate a plausible regulatory mechanism. [Figure not available: see fulltext.]

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood Cancer Journal
volume
13
issue
1
article number
139
publisher
Nature Publishing Group
external identifiers
  • pmid:37679323
  • scopus:85170083716
ISSN
2044-5385
DOI
10.1038/s41408-023-00914-7
language
English
LU publication?
yes
id
c87b67a2-3549-44d9-80dd-3a69af3593e8
date added to LUP
2023-10-19 10:13:56
date last changed
2024-10-04 19:34:47
@article{c87b67a2-3549-44d9-80dd-3a69af3593e8,
  abstract     = {{<p>The deregulation of BCL2 family proteins plays a crucial role in leukemia development. Therefore, pharmacological inhibition of this family of proteins is becoming a prevalent treatment method. However, due to the emergence of primary and acquired resistance, efficacy is compromised in clinical or preclinical settings. We developed a drug sensitivity prediction model utilizing a deep tabular learning algorithm for the assessment of venetoclax sensitivity in T-cell acute lymphoblastic leukemia (T-ALL) patient samples. Through analysis of predicted venetoclax-sensitive and resistant samples, PLK1 was identified as a cooperating partner for the BCL2-mediated antiapoptotic program. This finding was substantiated by additional data obtained through phosphoproteomics and high-throughput kinase screening. Concurrent treatment using venetoclax with PLK1-specific inhibitors and PLK1 knockdown demonstrated a greater therapeutic effect on T-ALL cell lines, patient-derived xenografts, and engrafted mice compared with using each treatment separately. Mechanistically, the attenuation of PLK1 enhanced BCL2 inhibitor sensitivity through upregulation of BCL2L13 and PMAIP1 expression. Collectively, these findings underscore the dependency of T-ALL on PLK1 and postulate a plausible regulatory mechanism. [Figure not available: see fulltext.]</p>}},
  author       = {{Shah, Kinjal and Nasimian, Ahmad and Ahmed, Mehreen and Al Ashiri, Lina and Denison, Linn and Sime, Wondossen and Bendak, Katerina and Kolosenko, Iryna and Siino, Valentina and Levander, Fredrik and Palm-Apergi, Caroline and Massoumi, Ramin and Lock, Richard B. and Kazi, Julhash U.}},
  issn         = {{2044-5385}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Nature Publishing Group}},
  series       = {{Blood Cancer Journal}},
  title        = {{PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia}},
  url          = {{http://dx.doi.org/10.1038/s41408-023-00914-7}},
  doi          = {{10.1038/s41408-023-00914-7}},
  volume       = {{13}},
  year         = {{2023}},
}